Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gossamer Bio (GOSS) EBITDA (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of EBITDA data on record, last reported at -$48.2 million in Q3 2025.

  • For Q3 2025, EBITDA fell 48.36% year-over-year to -$48.2 million; the TTM value through Sep 2025 reached -$159.0 million, down 117.09%, while the annual FY2024 figure was -$55.0 million, 69.38% up from the prior year.
  • EBITDA reached -$48.2 million in Q3 2025 per GOSS's latest filing, down from -$42.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $49.3 million in Q2 2024 and bottomed at -$59.4 million in Q3 2022.
  • Average EBITDA over 4 years is -$39.6 million, with a median of -$42.5 million recorded in 2023.
  • Peak YoY movement for EBITDA: soared 215.99% in 2024, then plummeted 186.21% in 2025.
  • A 4-year view of EBITDA shows it stood at -$55.8 million in 2022, then rose by 14.12% to -$47.9 million in 2023, then surged by 38.16% to -$29.6 million in 2024, then tumbled by 62.92% to -$48.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$48.2 million in Q3 2025, -$42.5 million in Q2 2025, and -$38.7 million in Q1 2025.